预约演示
更新于：2025-07-22
Drospirenone
屈螺酮
更新于：2025-07-22
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2019-05-23), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H30O3 |
InChIKeyMETQSPRSQINEEU-HXCATZOESA-N |
CAS号67392-87-4 |
关联
49
项与 屈螺酮 相关的临床试验NCT06608186
Can Drospirenone be Used to Prevent LH Surge in Controlled Ovarian Stimulation in PCOS Cases
NCT06345560
Pharmacokinetics of Drospirenone Only Pills in Obese Thai Women: A Pre- and Post-Bariatric Surgery Study
NCT06345586
Drospirenone Only Pills and Cervical Mucus Changes in Obese Thai Women: A Pre- and Post-Bariatric Surgery Study
100 项与 屈螺酮 相关的临床结果
登录后查看更多信息
100 项与 屈螺酮 相关的转化医学
登录后查看更多信息
100 项与 屈螺酮 相关的专利（医药）
登录后查看更多信息
1,456
项与 屈螺酮 相关的文献（医药）2025-12-31GYNECOLOGICAL ENDOCRINOLOGY
Medical treatment for adenomyosis: long term use of progestins
Article
作者: Vannuccini, Silvia ; Speciale, Anna Rosa ; Manzi, Virginia ; Toscano, Federico ; Petraglia, Felice ; Gallone, Angela ; Giani, Milo ; La Torre, Francesco ; Tureli, Dilruba
BACKGROUND:
Adenomyosis is a uterine disorder causing menstruation-related symptoms such as dysmenorrhea, heavy menstrual bleeding (HMB) and dyspareunia. A long-term management of the disease is required. Hormonal drugs are the most used, including a variety of progestins, even though few data are available on their long-term use in adenomyosis.
OBJECTIVE:
To evaluate the long-term efficacy of different progestins, including progestin-only pills (POP), for the management of adenomyosis-related symptoms.
METHODS:
A total of 140 patients (18-45 years) with adenomyosis were treated with progestins for at least three years. The treatment groups included dienogest (2 mg, n = 71), levonorgestrel-releasing intrauterine device (52 mg, n = 25), desogestrel (75 mcg, n = 20), and drospirenone (4 mg, n = 24). Symptoms were assessed using the Visual Analogue Scale (VAS) for pain and the Pictorial Blood Assessment Chart (PBAC) method for bleeding.
RESULTS:
Dienogest significantly reduced dysmenorrhea, dyspareunia, and HMB, with efficacy maintained over three years in most patients. However, after the first year 49% of patients required a switch to other treatments due to side effects or contraception need. The levonorgestrel-releasing intrauterine device also effectively managed HMB and pain, with 15% of patients switching treatment due to side effects. Both drospirenone and desogestrel improved HMB and dysmenorrhea, but desogestrel had a higher discontinuation rate due to reduced long-term efficacy. Norethisterone acetate was used as a second-line treatment in cases of intolerance or inadequate response.
CONCLUSION:
Progestins are effective for the long-term management of adenomyosis symptoms. The flexibility in switching between different progestins or routes of administration may help in optimizing outcomes.
2025-12-31GYNECOLOGICAL ENDOCRINOLOGY
Effect over coagulation and fibrinolysis parameters of a prolonged release 24 + 4 daily use regime contraceptive formulation containing 2 mg dienogest/0.02 mg ethinylestradiol
Article
作者: Regidor, Pedro-Antonio ; Angulo, Alicyoy ; Colli, Enrico
BACKGROUND:
A prolonged release combined oral contraceptive (COC) pill, containing 2 mg dienogest (DNG)/0.02 mg ethinylestradiol (EE) in a 24 + 4 daily dosing regimen has recently been approved in Europe.
OBJECTIVE:
To determine if this COC impacts coagulation and fibrinolytic factors in comparison to an immediate release COC containing 3 mg drospirenone (DRSP)/0.02 mg EE.
METHOD:
Forty-four patients received the novel product, and forty-seven the comparator (immediate release formulation) during nine complete cycles. Coagulation and fibrinolytic parameters were evaluated: activated protein C resistance ratio, Antithrombin III (AT III), C-reactive protein, Factor VII, Factor VIII, and D-Dimer.
RESULTS:
Compared to baseline, at the end of the study both groups displayed significantly higher mean values for AT III: 1.06 mg/mL (standard deviation [SD], 95% CI, 0.98-1.15) for the DNG/EE formulation and 1.04 mg/mL (SD 95% CI, 0.96-1.12) for the comparator (p = 0.0006 and p = 0.0009, respectively). D-dimer showed a non-significant slight reduction in the DNG/EE group, from 276.62 ng/mL (SD, 95% CI, 228.92-334.26) before treatment to 243.98 ng/mL (SD, 95% CI, 192.45-309.31) ng/mL after treatment. Contrarily, the comparator displayed a non-significant rise in D-dimer values from 246.46 ng/mL (SD, 95% CI, 205.44-295.66) ng/mL to 275.30 ng/mL (SD, 95% CI 219.21-345.75; p = 0.4520). All other parameters showed no significant differences before and after the treatment for both groups.
CONCLUSION:
The COC 2 mg DNG/0.02 mg EE was not associated with any meaningful changes in the analyzed coagulation and fibrinolytic parameters indicating that a prolonged release formulation does not impact on these factors.
CLINICAL TRIAL REGISTRY:
EudraCT: 2019-0018-77-97.
2025-08-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Pharmacological Treatments for Menopausal Vasomotor Symptoms: A Systematic Review and Bayesian Network Meta-Analysis of Efficacy and Safety
Review
作者: Saraiva, Cainã Araújo ; Oliveira Amador, Wellgner Fernandes ; Queiroz, Ivo ; Pinilla Alarcón, Juan Alejandro ; Roberto De Sa, Joao ; Iqbal, Asad ; de Souza Gaio, Giovana ; Ruelas, Mariano Gallo
OBJECTIVES:
To evaluate the efficacy and safety of pharmacological treatments for vasomotor symptoms (VMS) in postmenopausal women.
METHODS:
A systematic search was conducted in PubMed, Embase, and the Cochrane Library through January 2025. Eligible studies were Phase 3 or 4 randomized controlled trials (RCTs) assessing pharmacological treatments for moderate to severe VMS with ≥ 12 weeks of follow-up. A Bayesian random-effects network meta-analysis estimated mean differences (MDs) and risk ratios (RRs) with 95 % credible intervals (CrI). Treatments were ranked using surface under the cumulative ranking (SUCRA). Risk of bias was assessed using Cochrane's tool.
RESULTS:
Forty-one RCTs (n = 14,743; mean age 53.4 years) were included. Synthetic conjugated estrogens (SCE) 1.25 mg showed the greatest reduction in VMS frequency (MD -5.69; 95 % CrI -7.93 to -3.38), while drospirenone 0.5 mg + estradiol 0.5 mg was most effective for severity (MD -1.06; 95 % CrI -1.39 to -0.72). Most treatments had safety profiles similar to placebo, though estradiol 0.5 mg + dydrogesterone 2.5 mg was linked to more adverse events (RR 1.56; 95 % CrI 1.16 to 2.24). No significant differences in serious adverse events were found. SUCRA rankings highlighted SCE and transdermal estradiol gel as most effective for frequency, while drospirenone + estradiol led for severity. Fezolinetant and elinzanetant showed moderate efficacy. Of the studies, 22 had low risk of bias, and 19 had some concerns.
CONCLUSIONS:
Conjugated estrogens and drospirenone with estradiol are the most effective options for reducing VMS frequency and severity, and Fezolinetant and Elinzanetant showed moderate efficacy, with overall similar safety across treatments.
100 项与 屈螺酮 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 避孕 | 美国 | 2019-05-23 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 子宫内膜异位症 | 临床3期 | 斯洛伐克 | - | 2021-07-24 |
| 痛经 | 临床2期 | 日本 | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 30 | 憲願顧蓋鹹糧積醖鑰夢 = 遞鏇鹽獵醖襯積繭選網 鑰餘鏇壓觸夢餘選顧簾 (鏇簾鬱繭廠積膚鹽繭艱, 鏇淵廠獵觸觸膚蓋淵獵 ~ 醖鹽齋艱淵艱鹽選鏇觸) 更多 | - | 2024-04-19 | |||
憲願顧蓋鹹糧積醖鑰夢 = 衊鑰廠鏇積觸鑰鑰網構 鑰餘鏇壓觸夢餘選顧簾 (鏇簾鬱繭廠積膚鹽繭艱, 選鹽製鹽窪鑰艱鑰齋觸 ~ 鏇願壓壓鹽範選構蓋齋) 更多 | |||||||
N/A | - | (Nonobese participants) | 膚選窪鬱鏇選選鹽獵憲(製製糧壓膚網蓋窪衊簾) = 膚構繭夢繭糧鑰製願淵 範顧鹽觸願衊醖窪獵範 (積觸鹹築獵衊顧淵齋遞, 1.3 ~ 5.8) | 积极 | 2023-12-01 | ||
(Obese participants) | 膚選窪鬱鏇選選鹽獵憲(製製糧壓膚網蓋窪衊簾) = 築淵鏇鑰窪壓鬱衊廠遞 範顧鹽觸願衊醖窪獵範 (積觸鹹築獵衊顧淵齋遞, 0.8 ~ 7.3) | ||||||
N/A | - | - | Drospirenone-only pill | 衊鹽鹹鹽構淵壓觸製艱(廠蓋鏇構網餘獵觸構襯) = 獵艱鹹鹽遞窪繭窪顧範 築衊鏇淵鬱獵襯夢顧鏇 (願選鏇顧構範顧廠夢選 ) 更多 | 积极 | 2015-11-02 | |
Desogestrel-only pill | 衊鹽鹹鹽構淵壓觸製艱(廠蓋鏇構網餘獵觸構襯) = 築憲選壓選鬱獵網壓願 築衊鏇淵鬱獵襯夢顧鏇 (願選鏇顧構範顧廠夢選 ) 更多 | ||||||
N/A | 腹部肥胖 sex steroids | aldosteronism | 63 | 鹽廠選餘窪鏇鬱廠鹽築(築鬱獵鹹獵鹽齋齋蓋廠) = 積繭憲顧網獵襯遞製壓 鏇齋糧憲廠構壓蓋獵淵 (製築艱餘夢襯憲鏇鑰鬱 ) 更多 | 积极 | 2012-09-01 | ||
Hormone Replacement Therapy (estradiol hemihydrate 1 mg, drospirenone 2 mg daily) | 鹽廠選餘窪鏇鬱廠鹽築(築鬱獵鹹獵鹽齋齋蓋廠) = 壓遞餘製繭製壓鹹積範 鏇齋糧憲廠構壓蓋獵淵 (製築艱餘夢襯憲鏇鑰鬱 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用